Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03242278 · ClinicalTrials.gov registry record
Real-world Dosing Patterns of Rivaroxaban in the United States
A clinical trial of Atrial Fibrillation, sponsored by Bayer.
- Completed
- Registry status
- 12,507
- Enrollment target
- 1
- Study location
NCT03242278 is a study of Atrial Fibrillation that has completed, run by Bayer. The registered enrollment target is 12,507 participants, above the 2,935-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (326% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03242278, a study of Atrial Fibrillation, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 12,507 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to assess the proportion of Non-valvular atrial fibrillation (NVAF) patients receiving the standard dose of 20 mg of rivaroxaban or the reduced dose of 15 mg of rivaroxaban. The secondary objective is to determine if dosing patterns for rivaroxaban may be influenced by baseline chronic kidney disease (CKD) status (as a proxy for measured baseline renal function).
Conditions Studied
Interventions
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
Study Locations (1)
New York
- - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,507 participants |
| Start Date | 2016-02-12 |
| Est. Completion | 2016-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03242278
The ClinicalTrials.gov registry entry for NCT03242278 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12,507 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,935-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (326% higher). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Rivaroxaban (Xarelto, BAY59-7939) is the first listed.
NCT03242278 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03242278 about?
NCT03242278 is a clinical study titled "Real-world Dosing Patterns of Rivaroxaban in the United States". The primary objective is to assess the proportion of Non-valvular atrial fibrillation (NVAF) patients receiving the standard dose of 20 mg of rivaroxaban or the reduced dose of 15 mg of rivaroxaban. The secondary objective is to determine if dosing patterns for rivaroxaban may be influenced by base...
What is the current status of trial NCT03242278?
This trial is currently completed. The enrollment target is 12,507 participants. The study started on 2016-02-12. Estimated completion is 2016-03-01.
What conditions does trial NCT03242278 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT03242278?
The interventions under investigation include: Rivaroxaban (Xarelto, BAY59-7939) (DRUG).
Who is sponsoring clinical trial NCT03242278?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03242278 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.